# PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS

> **NCT07142291** · PHASE2 · RECRUITING · sponsor: **PhenoNet, Inc.** · enrollment: 105 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis (ALS)

## Interventions

- **DRUG:** Cromolyn Sodium (34.2 mg BID)
- **DRUG:** Cromolyn Sodium (17.1 mg BID)
- **DRUG:** Placebo
- **DRUG:** Riluzole (100 mg)

## Key facts

- **NCT ID:** NCT07142291
- **Lead sponsor:** PhenoNet, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-25
- **Primary completion:** 2027-11
- **Final completion:** 2028-03
- **Target enrollment:** 105 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07142291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07142291, "PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07142291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*